



Earnings Release

3Q21 and 9M21

Disclaimer

This presentation brings statements about future events that are subject to risks and uncertainties. Such statements are based on our Management's beliefs and assumptions and on information that the Company currently has access to. Statements about future events include information regarding our intentions, beliefs or current expectations, as well as those of the members of the Management Board and Company Directors.

Disclaimers according to the statements and the information about the future also include information about possible or presumed operating results, as well as statements preceded by, followed by or that include the words "believes", "may", "will", "continue", "expects", "anticipates", "intends", "plans", "estimates" or similar expressions.

The statements and information are not guarantees of future performance. They involve risks, uncertainties and assumptions because they are related to future events and, therefore, depending on circumstances that may or may not occur. Future results and value creation for our shareholders may differ materially from those expressed or implied by the statements made about the future. Many of the factors that will determine these results and values are beyond our ability to control or predict.

Kleber Gomes

Chief Executive Officer


Ourofino Saúde Animal is awarded as the best company in Latin and South America by Animal Health.

2022

- We Care
- We overcome obstacles
- We Care
- We expand the scenario
- We Care
- We increase the portfolio
- We Care
- We Invest
- We Innovate
- We Transform
- We reimagine
- We take care again



**Animal Health
Award Winner 2021**





For each of
our customers,
the whole of Our Culture.

Highlights

- ESG: materiality matrix prioritizing 6 themes
- Digital Transformation Journey
- Return to on-site activities in our offices and Ouflex Program
- Strong 2021





Angelo Melo

Strategic Development and


New Business Director

LAUNCH

Some issues take time to be solved.
For others, its better to act fast.

Conclue Line Diagnostic Kit

Precise instant results in favor of the one you love.



LAUNCHES

A new generation of vaccines with superior results*.

THE BEST OF THE FUTURE, REVOLUTIONIZING THE PRESENT.

Convenience, superior efficacy and long-lasting protection against enzootic Pneumonia.



Single dose protocol



Antigen with high expression of external proteins and high immunogenicity



Adjuvant that induces Cellular and mucosal immunity




Immunity duration of at least 25 weeks



*Ourofino internal studies
RE B192.AG1 / RE B192.AG2 / RE EC034.21

Ourovac for Rabies

Do not worry, you prevent rabies with Ourofino quality.



LAUNCHES

Guess who
came back?
You guessed right!
Highly effective
insecticide earring
"Na Mosca"



Highlights

- 21 new registered products in Mexico and Colombia this year
- Clostridium and Reproductive vaccines launch in Colombia in partnership




Marcelo Silva

CFO and IRO


Consolidated Results

Total Net Revenue and Gross Profit




Production Animals

Total Net Revenue and Gross Profit




Companion Animals

Total Net Revenue and Gross Profit





International Operations



Total Net Revenue and Gross Profit




SG&A




R&D Expenses



Adjusted Ebitda



Adjusted EBITDA margin %



Adjusted EBITDA margin %

Net Financial Expense and Income Tax


Net financial expense




Income tax



Adjusted Net Profit




Generation of Cash




Indebtedness

Net Debt



Aging of bank indebtedness



1.02x

0.84x


Net Debt/EBITDA

5.01%

7.35%

Annual Average interest on debt

R&D Investments





Q&A

Ourofino Saúde Animal
Participações S.A. (B3: OFSA3)
Investor Relations



ri@ourofino.com



+ 55 (16) 3518-2000



ri.ourofino.com